---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-003312"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:19:26.886736+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma Q1 net loss $4.9M; Berubicin interim analysis on track for Q3 2023

## Summary
- Net loss $4.9M vs $3.2M YoY; R&D expense $3.6M (+$1.7M) driven by CRO costs for Berubicin trial.
- Cash $5.1M at Mar 31; subsequent ATM raised ~$2.0M (avg $3.08/share) and ~$0.7M from warrant exercises.
- Enrollment >100 patients in potentially pivotal Berubicin GBM trial; 45 of 60 sites open across US and Europe.
- Interim analysis results expected Q3 2023; topline data after enrollment complete.
- Appointed Dr. Bettina Cockroft and Faith Charles to Board, strengthening biopharma and governance expertise.

## SEC filing metadata
- accession: 0001683168-23-003312
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316823003312/0001683168-23-003312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316823003312/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-003312
- JSON: https://secwatch.observer/filing/0001683168-23-003312.json
- Plain text: https://secwatch.observer/filing/0001683168-23-003312.txt

## Key facts
- Earnings Releases
  CNS Pharmaceuticals, Inc. reported the quarter ended March 31, 2023 results: net income approximately $4.9 million.
  - Period: the quarter ended March 31, 2023
  - Net income: approximately $4.9 million
  - Result: reported results
  source text: The net loss for the three months ended March 31, 2023 was approximately $4.9 million compared to approximately $3.2 million for the comparable period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316823003312/0001683168-23-003312-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.